Cancers like Merkel cell carcinoma (MCC) can evade the immune system by disrupting HLA class I antigen presentation, which is crucial for immune detection.
Researchers generated cell lines from MCC patients and found that certain genes responsible for HLA-I presentation were suppressed.
They identified two main regulators of HLA-I loss: MYCL and the PRC1.1 complex, with a focus on USP7 as a potential target for drug development to enhance HLA-I expression in MCC.